Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson's Disease.
Mammen JR, Speck RM, Stebbins GT, Müller MLTM, Yang PT, Campbell M, Cosman J, Crawford JE, Dam T, Hellsten J, Jensen-Roberts S, Kostrzebski M, Simuni T, Barowicz KW, Cedarbaum JM, Dorsey ER, Stephenson D, Adams JL. Mammen JR, et al. Among authors: cedarbaum jm. J Parkinsons Dis. 2023;13(4):619-632. doi: 10.3233/JPD-225068. J Parkinsons Dis. 2023. PMID: 37212071 Free PMC article.
Using a smartwatch and smartphone to assess early Parkinson's disease in the WATCH-PD study.
Adams JL, Kangarloo T, Tracey B, O'Donnell P, Volfson D, Latzman RD, Zach N, Alexander R, Bergethon P, Cosman J, Anderson D, Best A, Severson J, Kostrzebski MA, Auinger P, Wilmot P, Pohlson Y, Waddell E, Jensen-Roberts S, Gong Y, Kilambi KP, Herrero TR, Ray Dorsey E; Parkinson Study Group Watch-PD Study Investigators and Collaborators. Adams JL, et al. NPJ Parkinsons Dis. 2023 Apr 17;9(1):64. doi: 10.1038/s41531-023-00497-x. NPJ Parkinsons Dis. 2023. PMID: 37069193 Free PMC article.
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort.
Simuni T, Merchant K, Brumm MC, Cho H, Caspell-Garcia C, Coffey CS, Chahine LM, Alcalay RN, Nudelman K, Foroud T, Mollenhauer B, Siderowf A, Tanner C, Iwaki H, Sherer T, Marek K; Parkinson’s Progression Marker Initiative Authors. Simuni T, et al. NPJ Parkinsons Dis. 2022 Oct 22;8(1):140. doi: 10.1038/s41531-022-00404-w. NPJ Parkinsons Dis. 2022. PMID: 36273008 Free PMC article.
The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease.
DeBroff J, Omer N, Cohen B, Giladi N, Kestenbaum M, Shirvan JC, Cedarbaum JM, Gana-Weisz M, Goldstein O, Orr-Urtreger A, Mirelman A, Thaler A. DeBroff J, et al. Among authors: cedarbaum jm. Mov Disord Clin Pract. 2023 Mar 21;10(4):606-616. doi: 10.1002/mdc3.13722. eCollection 2023 Apr. Mov Disord Clin Pract. 2023. PMID: 37070047 Free PMC article.
Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease.
Thaler A, Livne V, Rubinstein E, Omer N, Faust-Socher A, Cohen B, Giladi N, Shirvan JC, Cedarbaum JM, Gana-Weisz M, Goldstein O, Orr-Urtreger A, Alcalay RN, Mirelman A. Thaler A, et al. Among authors: cedarbaum jm. Parkinsonism Relat Disord. 2024 Apr 16;123:106970. doi: 10.1016/j.parkreldis.2024.106970. Online ahead of print. Parkinsonism Relat Disord. 2024. PMID: 38691978
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials.
Genge A, Cedarbaum JM, Shefner J, Chio A, Al-Chalabi A, Van Damme P, McDermott C, Glass J, Berry J, van Eijk RPA, Fournier C, Grosskreutz J, Andrews J, Bertone V, Bunte TM, Couillard M, Cummings C, Kittle G, Polzer J, Salmon K, Straub C, van den Berg LH. Genge A, et al. Among authors: cedarbaum jm. Amyotroph Lateral Scler Frontotemporal Degener. 2024 May;25(3-4):382-387. doi: 10.1080/21678421.2024.2320880. Epub 2024 Feb 23. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38396337 Free article.
Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial.
Hutchison RM, Fraser K, Yang M, Fox T, Hirschhorn E, Njingti E, Scott D, Bedell BJ, Kistner KM, Cedarbaum JM, Evans KC, Graham D, Martarello L, Mollenhauer B, Lang AE, Dam T, Beaver J. Hutchison RM, et al. Among authors: cedarbaum jm. Neurology. 2024 Mar 12;102(5):e209137. doi: 10.1212/WNL.0000000000209137. Epub 2024 Feb 5. Neurology. 2024. PMID: 38315945 Clinical Trial.
Digital Mobility Measures: A Window into Real-World Severity and Progression of Parkinson's Disease.
Mirelman A, Volkov J, Salomon A, Gazit E, Nieuwboer A, Rochester L, Del Din S, Avanzino L, Pelosin E, Bloem BR, Della Croce U, Cereatti A, Thaler A, Roggen D, Mazza C, Shirvan J, Cedarbaum JM, Giladi N, Hausdorff JM. Mirelman A, et al. Among authors: cedarbaum jm. Mov Disord. 2024 Feb;39(2):328-338. doi: 10.1002/mds.29689. Epub 2023 Dec 27. Mov Disord. 2024. PMID: 38151859
Mapping Relevance of Digital Measures to Meaningful Symptoms and Impacts in Early Parkinson's Disease.
Mammen JR, Speck RM, Stebbins GM, Müller MLTM, Yang PT, Campbell M, Cosman J, Crawford JE, Dam T, Hellsten J, Jensen-Roberts S, Kostrzebski M, Simuni T, Barowicz KW, Cedarbaum JM, Dorsey ER, Stephenson D, Adams JL. Mammen JR, et al. Among authors: cedarbaum jm. J Parkinsons Dis. 2023;13(4):589-607. doi: 10.3233/JPD-225122. J Parkinsons Dis. 2023. PMID: 37212073 Free PMC article.
A qualitative evaluation of the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) by the patient community: a web-based cross-sectional survey.
Boyce D, Robinson M, Cedarbaum JM, Shank LM, McDermott CJ, van Eijk RPA. Boyce D, et al. Among authors: cedarbaum jm. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3-4):272-280. doi: 10.1080/21678421.2022.2140592. Epub 2022 Nov 4. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36330850
123 results